Antipsychotics and COVID-19: the debate goes on
- PMID: 34801118
- PMCID: PMC8601681
- DOI: 10.1016/S2215-0366(21)00396-5
Antipsychotics and COVID-19: the debate goes on
Conflict of interest statement
We declare no competing interests.
Comment in
-
Antipsychotics and COVID-19: the debate goes on - Authors' reply.Lancet Psychiatry. 2021 Dec;8(12):1030-1031. doi: 10.1016/S2215-0366(21)00428-4. Lancet Psychiatry. 2021. PMID: 34801117 Free PMC article. No abstract available.
Comment on
-
Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis.Lancet Psychiatry. 2021 Sep;8(9):797-812. doi: 10.1016/S2215-0366(21)00232-7. Epub 2021 Jul 17. Lancet Psychiatry. 2021. PMID: 34274033 Free PMC article.
Similar articles
-
Antipsychotics and COVID-19: the debate goes on - Authors' reply.Lancet Psychiatry. 2021 Dec;8(12):1030-1031. doi: 10.1016/S2215-0366(21)00428-4. Lancet Psychiatry. 2021. PMID: 34801117 Free PMC article. No abstract available.
-
Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses.Braz J Psychiatry. 2021 Sep-Oct;43(5):462-464. doi: 10.1590/1516-4446-2020-0024. Braz J Psychiatry. 2021. PMID: 33440401 Free PMC article. No abstract available.
-
The role of antipsychotics against COVID-19: A topic for debate.Schizophr Res. 2021 Sep;235:5-6. doi: 10.1016/j.schres.2021.07.003. Epub 2021 Jul 8. Schizophr Res. 2021. PMID: 34274797 Free PMC article. No abstract available.
-
Progress in understanding COVID-19: insights from the omics approach.Crit Rev Clin Lab Sci. 2021 Jun;58(4):242-252. doi: 10.1080/10408363.2020.1851167. Epub 2020 Dec 29. Crit Rev Clin Lab Sci. 2021. PMID: 33375876 Review.
-
COVID-19, SARS -CoV-2, Origin, Transmission and Treatment Aspects, A Brief Review.Infect Disord Drug Targets. 2021;21(5):e270421186673. doi: 10.2174/1871526520666201006163641. Infect Disord Drug Targets. 2021. PMID: 33023459 Review.
Cited by
-
Adherence to Antipsychotics, COVID-19 and Stigma: A Rainbow After the Storm?Actas Esp Psiquiatr. 2025 May;53(3):616-620. doi: 10.62641/aep.v53i3.1813. Actas Esp Psiquiatr. 2025. PMID: 40356005 Free PMC article.
-
Epidemiology of infection, transmission and COVID-19 outcomes among mental health users and workers in a comprehensive network of long-term mental health facilities: Retrospective observational population-base study.Schizophr Res. 2023 Apr;254:1-7. doi: 10.1016/j.schres.2023.01.020. Epub 2023 Jan 20. Schizophr Res. 2023. PMID: 36736100 Free PMC article.
-
Antipsychotics, COVID-19, and Secondary Healthcare Databases: Revisiting the Pandemic.Int J Neuropsychopharmacol. 2024 Jul 1;27(7):pyae026. doi: 10.1093/ijnp/pyae026. Int J Neuropsychopharmacol. 2024. PMID: 38878266 Free PMC article. No abstract available.
-
Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients.Pharmaceutics. 2022 Aug 30;14(9):1828. doi: 10.3390/pharmaceutics14091828. Pharmaceutics. 2022. PMID: 36145576 Free PMC article.
-
Aripiprazole as protector against COVID-19 mortality.Sci Rep. 2024 May 29;14(1):12362. doi: 10.1038/s41598-024-60297-y. Sci Rep. 2024. PMID: 38811612 Free PMC article.
References
-
- Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274–280. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical